InMed Pharmaceuticals Completes Merger with Mentari Therapeutics

InMed Pharmaceuticals completed its merger with privately held Mentari Therapeutics, and the combined company will operate as Mentari Therapeutics, Inc. The company also completed its redomestication from British Columbia to Nevada. Before the merger, Mentari completed private financings totaling approximately $490 million in gross proceeds, including the conversion of $50 million in convertible notes plus accrued interest. The combined company’s shares are expected to begin trading on the Nasdaq Capital Market under ticker MTRI on November 9, 2026.